Get the Stockscreener App
3.58
7.25%
-0.28
Pre-market:
3.55
-0.03
-0.84%
Precigen Inc stock is traded at $3.58, with a volume of 5.31M.
It is down -7.25% in the last 24 hours and down -17.32% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$3.86
Open:
$3.84
24h Volume:
5.31M
Relative Volume:
1.22
Market Cap:
$1.28B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-2.5575
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
-17.51%
1M Performance:
-17.32%
6M Performance:
-0.56%
1Y Performance:
+169.17%
1-Day Range:
$3.53
$3.875
1-Week Range:
$3.53
$4.40
52-Week Range:
$1.35
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.58 | 1.38B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen, Inc. (PGEN) is a great momentum stock: Should you buy? - MSN
Precigen jumps after Q1 beat as Papzimeos launch momentum takes hold - MSN
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability - 富途牛牛
Have Precigen Insiders Been Selling Stock? - simplywall.st
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
H.C. Wainwright reiterates Precigen stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Precigen stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Precigen CCO Phil Tennant sells $131,985 in stock By Investing.com - Investing.com Australia
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock By Investing.com - Investing.com South Africa
Precigen chief legal officer Lehr sells $127,011 in stock By Investing.com - Investing.com India
Precigen COO Rutul R Shah sells $186,185 in common stock By Investing.com - Investing.com India
Precigen chief legal officer Lehr sells $127,011 in stock - Investing.com
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock By Investing.com - Investing.com Australia
Precigen COO Rutul R Shah sells $186,185 in common stock - Investing.com
Precigen CCO Phil Tennant sells $131,985 in stock - Investing.com
Precigen (PGEN) CEO sells 119,250 shares in tax sell-to-cover transaction - Stock Titan
Precigen (PGEN) CFO sells 41,884 shares to cover RSU tax withholding - Stock Titan
PRECIGEN (PGEN) CCO sells 30,272 shares in tax-related transaction - Stock Titan
Precigen (PGEN) COO sells 42,703 shares to cover RSU tax withholding - Stock Titan
Precigen (PGEN) Chief Legal Officer sells shares to cover RSU tax withholding - Stock Titan
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Promising Long-Term Data for Precigen (PGEN) in RRP Treatment - GuruFocus
Precigen Q1 earnings call highlights - MSN
Number of shareholders of Precigen, Inc. – NASDAQ:PGEN - TradingView
Number of shareholders of Precigen Inc – BX:I5X - TradingView
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PR Newswire
Precigen (PGEN) price target increased by 11.76% to 9.69 - MSN
Precigen(PGEN) Stock Options Chain | Quotes & News - Moomoo
Precigen (PGEN) Maintained by HC Wainwright & Co. -- Price Targe - GuruFocus
Precigen Q1 2026 Earnings: Narrowed Loss Exceeds Expectations as Stock RisesMargin Compression Risk - The Legal Advocate
Precigen (PGEN) CFO gains 87,500 shares from RSU vesting - Stock Titan
PRECIGEN (PGEN) CCO Phil Tennant acquires 62,500 shares through RSU vesting - Stock Titan
Precigen (PGEN) COO converts 90,000 RSUs to common shares in Form 4 filing - Stock Titan
Precigen’s PAPZIMEOS Receives FDA Orphan Drug Exclusivity for RRP Treatment, Blocking Similar Drugs for Seven Years - geneonline.com
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS - Investing.com UK
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - ACCESS Newswire
Precigen (PGEN) Secures Orphan Drug Status for Papzimeos Treatme - GuruFocus
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapog - GuruFocus
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS By Investing.com - Investing.com Australia
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tennant Phil | Chief Commercial Officer |
May 28 '26 |
Sale |
4.36 |
30,272 |
131,986 |
139,369 |
| Shah Rutul R | Chief Operating Officer |
May 28 '26 |
Sale |
4.36 |
42,703 |
186,185 |
497,751 |
| Lehr Donald P. | Chief Legal Officer |
May 28 '26 |
Sale |
4.36 |
29,131 |
127,011 |
755,461 |
| Sabzevari Helen | President and CEO |
May 28 '26 |
Sale |
4.36 |
119,250 |
519,930 |
3,768,872 |
| KIRK RANDAL J | Director |
Mar 30 '26 |
Sale |
3.30 |
4,772,781 |
15,750,177 |
302,213 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):